Can Blindness Be Genetic? Understanding Inherited Vision Loss

Blindness can absolutely be genetic, and inherited causes of vision loss are far more common than most people realize. Hundreds of different genes have been linked to conditions that damage the retina, the optic nerve, or other parts of the visual system, sometimes causing blindness from birth and sometimes triggering a slow decline over decades. The way these conditions are passed down varies widely, from straightforward single-gene inheritance to complex multi-gene patterns where lifestyle also plays a role.

How Inherited Vision Loss Gets Passed Down

Inherited retinal diseases are caused by mutations in genes essential for the retina to develop or function properly. What makes the genetics complicated is the sheer number of genes involved and the different ways they can be inherited. A large study of over 2,000 genetically solved cases in Italy found that autosomal recessive inheritance was by far the most common pattern, accounting for about 72% of cases. Autosomal dominant forms represented roughly 14%, and X-linked forms made up about 12%.¹

In practical terms, autosomal recessive means both parents carry one copy of a faulty gene without being affected themselves. Each of their children has a one-in-four chance of inheriting both faulty copies and developing the condition. Because carriers show no symptoms, these diseases often seem to appear out of nowhere in a family. Autosomal dominant conditions, by contrast, require only one faulty copy, so an affected parent has a 50-50 chance of passing it on to each child. X-linked conditions mostly affect boys, because they have only one X chromosome and no backup copy to compensate for a mutation.

There is also a fourth, less common route: mitochondrial inheritance. Mitochondria, the energy-producing structures inside cells, carry their own small set of DNA, and mutations there are passed exclusively from mother to child. Leber hereditary optic neuropathy is the best-known example. It disproportionately affects young men, even though both sons and daughters inherit the mutation from their mothers.²

Retinitis Pigmentosa

Retinitis pigmentosa, or RP, is one of the most well-known inherited retinal diseases. It starts by killing rod photoreceptors, the cells responsible for vision in dim light, which is why the first symptom is almost always difficulty seeing at night. Over years or decades, the loss of peripheral vision follows, creating a shrinking tunnel of sight that can eventually close entirely.³

What makes RP particularly frustrating from a genetic standpoint is that mutations in dozens of different genes can cause it, and the condition can follow autosomal dominant, autosomal recessive, or X-linked inheritance depending on which gene is involved. Two people with RP might have completely different genetic causes and different rates of progression. Adding to the puzzle, the genetic mutation in every form of RP is expressed only in rods, yet cone photoreceptors (the ones responsible for color and central vision) eventually die too.⁴ Researchers believe this secondary cone death involves a cascade of metabolic stress, oxidative damage, and loss of the chemical support rods normally provide to their cone neighbors.⁵

Stargardt Disease

While RP attacks from the periphery inward, Stargardt disease does roughly the opposite: it destroys central vision first. It is the most common form of inherited macular degeneration, typically showing up in childhood or adolescence. A teenager might notice that reading becomes harder, colors look faded, or there is a blurry spot right in the center of their visual field.

Stargardt disease is usually caused by mutations in the ABCA4 gene and follows autosomal recessive inheritance. The ABCA4 gene codes for a transporter protein in photoreceptors that helps clear away toxic byproducts of the visual cycle. When this transporter does not work properly, a fatty waste material called lipofuscin builds up in the retinal pigment epithelium, the support layer beneath the photoreceptors.⁶ Over time, this buildup poisons the support cells and causes the photoreceptors above them to degenerate.⁷ Because both parents must carry one copy of the faulty gene, families with no history of vision problems can still have an affected child.

Leber Congenital Amaurosis

At the severe end of the spectrum sits Leber congenital amaurosis, or LCA, which causes profound vision loss in infancy or early childhood. Parents typically notice within the first year of life that their baby does not visually track objects or respond normally to light. LCA is rare, with a prevalence estimated at roughly 1 in 80,000, and it accounts for about 5% of all inherited retinal diseases and around 20% of children in schools for the blind.⁸

More than 20 different genes have been linked to LCA, each affecting a different aspect of retinal function. Mutations in the RPE65 gene are responsible for roughly 6% of LCA cases, and this particular form has become the poster child for gene therapy in ophthalmology, as we will see below. Despite the shared label of “LCA,” the clinical picture can vary depending on the gene involved: some children retain small islands of useful vision into adulthood, while others are virtually blind from birth.

Leber Hereditary Optic Neuropathy

Confusingly, Leber hereditary optic neuropathy (LHON) shares a name with Leber congenital amaurosis but is a completely different disease with a different inheritance pattern and a different target in the eye. LHON attacks the optic nerve rather than the retina, causing sudden painless vision loss, often in one eye first and then the other within weeks or months. It predominantly affects young men, typically between the ages of 15 and 35, even though both men and women inherit the mitochondrial mutation from their mothers.⁹

More than 95% of LHON cases trace to one of three specific point mutations in mitochondrial DNA, all affecting parts of the energy-production machinery inside cells.² What remains poorly understood is why some people carrying these mutations lose their sight and others do not. Only about half of men and roughly 10 to 15% of women who carry one of the primary mutations actually develop symptoms. Environmental triggers like tobacco and heavy alcohol use appear to increase the risk, and the broader mitochondrial DNA background a person inherits may shift the odds as well.¹⁰

When Blindness Is Part of a Larger Syndrome

Some genetic conditions cause vision loss alongside problems in other organ systems. The most common of these is Usher syndrome, which combines sensorineural hearing loss with retinitis pigmentosa and, in some cases, problems with balance. Usher syndrome accounts for an estimated 10 to 20% of all RP cases, making it the single most common genetic cause of combined deafness and blindness.¹¹

Usher syndrome is autosomal recessive and is classified as a ciliopathy, meaning it results from defects in cilia, the tiny hair-like structures found on the surface of most cells in the body. In the inner ear, the proteins affected by Usher mutations are critical for the development and maintenance of the stereocilia that detect sound vibrations. In the retina, cilia serve as the highway that transports visual pigment molecules within photoreceptors. When these transport systems fail, both hearing and vision deteriorate.¹² Children with Usher syndrome are often identified first through newborn hearing screening and may not develop noticeable vision problems until their teens or later, when RP symptoms begin to emerge.¹³

When Genetics Is Only Part of the Story

Not all genetically influenced eye disease follows the neat pattern of one gene, one condition. Age-related macular degeneration (AMD), the leading cause of vision loss in older adults in developed countries, is driven by a combination of genetic risk variants, natural aging, and lifestyle factors like smoking and diet.¹⁴ Many of the strongest genetic risk variants cluster in genes of the complement system, part of the immune response. One well-studied variant in the C3 gene roughly doubles the risk of AMD in people who carry two copies compared to those with none.¹⁵ But carrying the variant does not guarantee you will develop the disease, and avoiding it does not guarantee you will not. Epigenetic changes, the chemical modifications to DNA that accumulate over a lifetime in response to environmental exposures, also play a role in AMD susceptibility and progression.¹⁶

Glaucoma is another condition where genetics tells only part of the story. Some forms of early-onset glaucoma have clear single-gene causes. In one study of 60 patients with juvenile or early-onset glaucoma, mutations in MYOC were found in about 13% and mutations in CYP1B1 in about 5%, with evidence that the two genes may interact in a digenic pattern.¹⁷ But the much more common form of glaucoma in older adults involves many small-effect genetic variants layered on top of risk factors like high eye pressure and age.

What Genetic Testing Can and Cannot Tell You

If you or a family member receives a diagnosis of an inherited retinal disease, genetic testing is usually the next step. Modern sequencing technology can screen hundreds of known eye-disease genes at once. A systematic review and meta-analysis of studies using next-generation sequencing for inherited retinal diseases found an overall diagnostic yield of about 61% for mixed groups of patients.¹⁸ That means roughly six out of ten people tested get a definitive genetic answer. The yield was somewhat higher in more recent studies and when broader exome sequencing was used rather than narrower gene panels.

A diagnostic yield of 61% is encouraging, but it also means nearly four in ten people walk away without a clear genetic answer. Sometimes the responsible gene has not been identified yet. Other times the mutation is in a region of the genome that current technology has trouble reading. A study from a multi-ethnic Asian cohort reported a lower overall diagnostic yield of about 49%, a reminder that reference databases and variant interpretation can be influenced by the populations they were built from.¹⁹ If your first test comes back negative, it does not necessarily mean your condition is not genetic; it may just mean the cause has not been found yet.

Gene Therapy Arrives

The most dramatic development in inherited vision loss in the past decade has been gene therapy. In 2017, the FDA approved voretigene neparvovec (brand name Luxturna), the first gene therapy for any genetic disease in the United States. It works by delivering a healthy copy of the RPE65 gene directly into the retina using a harmless viral vector.²⁰ In follow-up studies, the majority of treated patients reported improvements in night vision, daytime vision, or color vision, though the degree of benefit varied. Pediatric patients tended to show more measurable improvement than adults, likely because younger retinas still have more surviving photoreceptors to rescue.²¹

Gene editing using CRISPR-Cas9 represents the next frontier. Rather than adding a new copy of a gene, CRISPR can correct or remove a specific mutation within the patient’s own DNA. Researchers have shown this approach can work in laboratory and animal models for LCA caused by mutations in the CEP290 gene.²² A small phase 1-2 human trial of an in vivo CRISPR treatment called EDIT-101 for this same mutation showed an acceptable safety profile and improvements in photoreceptor function, supporting further research.²³ The promise is enormous, but each gene therapy or gene-editing treatment targets one specific mutation, so scaling these approaches across the hundreds of genes involved in inherited blindness will take time.

Stem Cell Approaches for Advanced Disease

Gene therapy works best when there are still living photoreceptors to save. For people whose retinal cells have already been lost, stem cell-based strategies aim to replace the damaged tissue entirely. Researchers have generated retinal pigment epithelium cells from induced pluripotent stem cells (iPSCs, essentially adult cells reprogrammed back to a flexible state) and transplanted them under the retinas of patients with advanced macular degeneration. In an early feasibility study, a transplanted sheet of iPSC-derived cells remained intact a year after surgery, though visual acuity did not improve.²⁴

A key challenge is keeping transplanted cells alive and functional without triggering immune rejection. In animal models, iPSC-derived retinal cells from immune-matched donors survived without immunosuppression, while mismatched grafts provoked immune attacks and tissue damage.²⁵ Newer work has produced clinical-grade iPSC-derived RPE patches grown on biodegradable scaffolds, which showed improved integration and function compared to cells injected as a loose suspension in rat and pig models.²⁶ These approaches are still experimental, but they represent a potential option for people for whom gene therapy has come too late.

Genetic Counseling and Family Planning

For families affected by inherited vision loss, understanding the genetics is not just academic. It shapes deeply personal decisions about having children. Genetic counseling can help clarify the inheritance pattern, estimate risks for future pregnancies, and lay out reproductive options like preimplantation genetic testing (PGT), which allows embryos to be screened before implantation during IVF. In qualitative interviews, people with genetic visual loss expressed enthusiasm for genetic testing because it helped them understand whether relatives might be affected, and many viewed PGT positively as a way to have a child without the causative mutation while avoiding the prospect of terminating a pregnancy.²⁷

These decisions are anything but straightforward. A cross-sectional study of Chinese families with inherited retinal disease found that willingness to pursue genetic testing and reproductive screening was shaped by a mix of clinical, financial, and emotional factors. Parents who reported concern about their child’s future marriage prospects were more willing to pursue testing, while cost was a significant barrier, especially for families of girls. Parents who themselves had severe vision impairment were initially less willing to test but more open to assisted reproductive technologies once counseled.²⁸ The takeaway is that genetic counseling at specialized eye-disease centers plays a critical role in helping families navigate options that are as emotionally charged as they are medically complex.

The Access Problem

Even when a gene therapy exists, getting it to the people who need it is another matter entirely. Luxturna carries a list price of around $850,000 for both eyes in the United States. As of early 2025, FDA-approved cell and gene therapy products ranged in price from roughly $275,000 to over $4 million, and most of the clinical research leading to these approvals takes place in high-income countries.²⁹ For families in low- and middle-income countries, where inherited retinal diseases are just as common and consanguinity rates can increase the prevalence of recessive conditions, these therapies remain largely out of reach. Resolving the gap between what is scientifically possible and what is practically available is one of the defining challenges in this field going forward.